Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Magn Reson Med. 2014 Dec 17;74(6):1750–1757. doi: 10.1002/mrm.25566

Figure 5. MntR* expression and dual expression of DMT1 and MntR* allow for extended contrast in a B16 melanoma model.

Figure 5

(a) In a dual tumor model using control and MntR*-expressing (+MntR*) B16 cells, +MntR* tumors produced visually obvious contrast over control B16 cells at 3 and 6 hours (tumors marked by white arrows). (b) Similarly, dual expression of DMT1 and MntR* (+D+M) showed obvious contrast compared to controls at both time points. (c) In time course experiments, contrast measured in +MntR* and +D+M tumors, compared to B16 controls (n=5 mice for each tumor type), showed persistent and significant positive increases in signal intensity, creating up to 25% contrast in vivo. (See text for the results of the statistical analyses).